Ginkgo Bioworks Receives Notice Of Continued Listing Standard Notice From NYSE
Portfolio Pulse from Benzinga Newsdesk
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) received a notice from the NYSE on May 7, 2024, for not complying with the minimum average closing price requirement of $1 per share over a consecutive 30 trading-day period. Despite this, Ginkgo's Class A common stock continues to trade on the NYSE.
May 13, 2024 | 8:10 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Ginkgo Bioworks received a notice from the NYSE for not meeting the minimum average closing price, posing a risk of future delisting if compliance is not regained.
Receiving a notice from the NYSE for not meeting the minimum average closing price requirement is a significant regulatory issue that can lead to delisting if not addressed. This situation puts negative pressure on the stock as it raises concerns among investors about the company's ability to maintain its listing status. The immediate impact is likely negative due to potential investor concern over the financial health and future of the company.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100